Trabedersen

Identification

Generic Name
Trabedersen
DrugBank Accession Number
DB05697
Background

Not Available

Type
Biotech
Groups
Investigational
Biologic Classification
Nucleic Acid Based Therapies
Oligonucleotides
Synonyms
  • DNA, D(P-THIO)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A)
External IDs
  • A-12009 FREE ACID

Pharmacology

Indication

Investigated for use/treatment in brain cancer, colorectal cancer, melanoma, and pancreatic cancer.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action

AP 12009 is an antisense oligodeoxynucleotide that specifically inhibits TGF-beta2. TGF-beta overexpression is a hallmark of various malignant tumors. This is due to the pivotal role of TGF-beta as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation.

TargetActionsOrganism
UTransforming growth factor beta-2Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AmbroxolThe risk or severity of methemoglobinemia can be increased when Trabedersen is combined with Ambroxol.
ArticaineThe risk or severity of methemoglobinemia can be increased when Trabedersen is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Trabedersen is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Trabedersen is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Trabedersen is combined with Bupivacaine.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Trabedersen sodiumQ037WFO97F871479-94-6Not applicable
International/Other Brands
Oncomun

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
98OYR854NY
CAS number
925681-61-4

References

General References
  1. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P: Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):129-39. Epub 2005 Dec 27. [Article]
Not Available

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
3TerminatedTreatmentAnaplastic Astrocytoma (AA) / High Grade Glioma: Glioblastoma (GBM)1somestatusstop reasonjust information to hide
2CompletedTreatmentAnaplastic Astrocytoma (AA) / High Grade Glioma: Glioblastoma (GBM)1somestatusstop reasonjust information to hide
2Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19)1somestatusstop reasonjust information to hide
2WithdrawnTreatmentMetastatic Non-Small Cell Lung Cancer / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Lung Cancer AJCC v81somestatusstop reasonjust information to hide
1CompletedTreatmentColorectal Neoplasms / Melanoma / Pancreatic Neoplasms1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Type iii transforming growth factor beta receptor binding
Specific Function
TGF-beta 2 has suppressive effects on interleukin-2 dependent T-cell growth.
Gene Name
TGFB2
Uniprot ID
P61812
Uniprot Name
Transforming growth factor beta-2
Molecular Weight
47747.275 Da
References
  1. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, Hau P, Bogdahn U, Fischer-Blass B, Jachimczak P: Targeted tumor therapy with the TGF-beta 2 antisense compound AP 12009. Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):129-39. Epub 2005 Dec 27. [Article]

Drug created at November 18, 2007 18:27 / Updated at May 05, 2021 20:39